Analyst Ratings

Upgrades, downgrades, and outlook changes from major analysts.

Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.

Articles

1,424 total articles

Bernstein SocGen Lowers Freeport-McMoRan Rating Amid Valuation Concerns Despite Operational Gains

Bernstein SocGen Lowers Freeport-McMoRan Rating Amid Valuation Concerns Despite Operational Gains

Bernstein SocGen Group has downgraded Freeport-McMoRan’s stock from Outperform to Market Perform, even as the mining giant shows signs of steady recovery following disruptions at its Grasberg site. Despite operational improvements and increased production guidance, the analyst remains wary of the stock’s valuation, which currently reflects optimist…

TD Cowen Adjusts Abbott Laboratories Price Target Citing Q4 Revenue Shortfall and Moderated 2026 Outlook

TD Cowen Adjusts Abbott Laboratories Price Target Citing Q4 Revenue Shortfall and Moderated 2026 Outlook

TD Cowen has lowered its price target for Abbott Laboratories following the company's fourth-quarter revenue and earnings misses, accompanied by cautious sales guidance for 2026. While sharing a subdued outlook, TD Cowen retains a Buy rating, citing attractive valuation levels and expected improvements in Diagnostics and Nutrition segments over tim…

Benchmark Affirms Buy Rating for USA Rare Earth Amid Progress on Round Top Mine and European Expansion

Benchmark Affirms Buy Rating for USA Rare Earth Amid Progress on Round Top Mine and European Expansion

Benchmark has upheld a Buy recommendation and a $15 price target on USA Rare Earth's stock, following the company’s recent updates on its Round Top mine initiative in Texas and its expansion plans in Europe. Despite the stock trading above this price, the current valuation appears elevated relative to Benchmark's assessment. The company’s collabora…

Benchmark Maintains Buy Rating on CSX Amid Focus on Efficiency Gains

Benchmark Maintains Buy Rating on CSX Amid Focus on Efficiency Gains

Benchmark reaffirmed its Buy rating and a $40 price target for CSX following the railroad company’s fourth-quarter earnings release. Despite missing earnings estimates and ongoing challenges in revenue growth, the company’s management projects modest revenue increases and improved operating efficiency in 2026, underpinned by substantial cost-saving…

Benchmark Upholds Buy Rating on IMAX Amid Robust Box Office Performance and Promising 2026 Outlook

Benchmark Upholds Buy Rating on IMAX Amid Robust Box Office Performance and Promising 2026 Outlook

Benchmark has reaffirmed its Buy rating and $42 price target for IMAX Corporation (NYSE:IMAX) following impressive fourth-quarter results and positive indicators for 2026 box office revenue. Driving momentum is the successful international rollout of "Avatar: Fire and Ash" and the introduction of new releases along with varied content offerings, po…